HUE036182T2 - DHA és más LC-PUFA elõállítása növényekben - Google Patents

DHA és más LC-PUFA elõállítása növényekben

Info

Publication number
HUE036182T2
HUE036182T2 HUE11784114A HUE11784114A HUE036182T2 HU E036182 T2 HUE036182 T2 HU E036182T2 HU E11784114 A HUE11784114 A HU E11784114A HU E11784114 A HUE11784114 A HU E11784114A HU E036182 T2 HUE036182 T2 HU E036182T2
Authority
HU
Hungary
Prior art keywords
pufa
dha
plants
preparation
Prior art date
Application number
HUE11784114A
Other languages
English (en)
Hungarian (hu)
Inventor
Terence A Walsh
Ann Owens Merlo
Daniel Gachotte
Paul Gordon Roessler
Scott Bevan
Jerry M Kuner
James G Metz
Original Assignee
Dow Agrosciences Llc
Dsm Ip Assets Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dow Agrosciences Llc, Dsm Ip Assets Bv filed Critical Dow Agrosciences Llc
Publication of HUE036182T2 publication Critical patent/HUE036182T2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8243—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits involving biosynthetic or metabolic pathways, i.e. metabolic engineering, e.g. nicotine, caffeine
    • C12N15/8247—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits involving biosynthetic or metabolic pathways, i.e. metabolic engineering, e.g. nicotine, caffeine involving modified lipid metabolism, e.g. seed oil composition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
    • C12P7/6409—Fatty acids
    • C12P7/6427—Polyunsaturated fatty acids [PUFA], i.e. having two or more double bonds in their backbone
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
    • C12P7/6409—Fatty acids
    • C12P7/6427—Polyunsaturated fatty acids [PUFA], i.e. having two or more double bonds in their backbone
    • C12P7/6432—Eicosapentaenoic acids [EPA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
    • C12P7/6409—Fatty acids
    • C12P7/6427—Polyunsaturated fatty acids [PUFA], i.e. having two or more double bonds in their backbone
    • C12P7/6434—Docosahexenoic acids [DHA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1025—Acyltransferases (2.3)
    • C12N9/1029—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1288—Transferases for other substituted phosphate groups (2.7.8)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
HUE11784114A 2010-05-17 2011-05-17 DHA és más LC-PUFA elõállítása növényekben HUE036182T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US34553710P 2010-05-17 2010-05-17

Publications (1)

Publication Number Publication Date
HUE036182T2 true HUE036182T2 (hu) 2018-06-28

Family

ID=44992026

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE11784114A HUE036182T2 (hu) 2010-05-17 2011-05-17 DHA és más LC-PUFA elõállítása növényekben

Country Status (25)

Country Link
US (5) US20130150599A1 (cg-RX-API-DMAC7.html)
EP (3) EP2571994B1 (cg-RX-API-DMAC7.html)
JP (1) JP6059138B2 (cg-RX-API-DMAC7.html)
KR (1) KR102184432B1 (cg-RX-API-DMAC7.html)
CN (2) CN103080319B (cg-RX-API-DMAC7.html)
AR (1) AR081201A1 (cg-RX-API-DMAC7.html)
AU (1) AU2011256209B2 (cg-RX-API-DMAC7.html)
BR (1) BR112012029255A2 (cg-RX-API-DMAC7.html)
CA (2) CA3161375A1 (cg-RX-API-DMAC7.html)
CL (1) CL2012003210A1 (cg-RX-API-DMAC7.html)
EA (1) EA201291223A1 (cg-RX-API-DMAC7.html)
ES (1) ES2656217T3 (cg-RX-API-DMAC7.html)
HU (1) HUE036182T2 (cg-RX-API-DMAC7.html)
IL (1) IL223045A0 (cg-RX-API-DMAC7.html)
MX (1) MX345243B (cg-RX-API-DMAC7.html)
MY (1) MY165098A (cg-RX-API-DMAC7.html)
NO (1) NO2571994T3 (cg-RX-API-DMAC7.html)
NZ (1) NZ604479A (cg-RX-API-DMAC7.html)
PH (1) PH12012502267A1 (cg-RX-API-DMAC7.html)
PL (1) PL2571994T3 (cg-RX-API-DMAC7.html)
PT (1) PT2571994T (cg-RX-API-DMAC7.html)
SG (1) SG185572A1 (cg-RX-API-DMAC7.html)
TW (1) TW201144442A (cg-RX-API-DMAC7.html)
UA (1) UA116613C2 (cg-RX-API-DMAC7.html)
WO (1) WO2011146524A1 (cg-RX-API-DMAC7.html)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11236351B2 (en) * 2010-05-17 2022-02-01 Dow Agrosciences Llc Production of DHA and other LC PUFAs in plants
TW201144442A (en) * 2010-05-17 2011-12-16 Dow Agrosciences Llc Production of DHA and other LC-PUFAs in plants
MX2013005583A (es) * 2010-12-30 2013-07-05 Ericsson Telefon Ab L M Metodos y aparatos para permitir indicacion de reduccion de potencia en reporte de margen de potencia en un sistema de telecomunicaciones.
TW201307553A (zh) * 2011-07-26 2013-02-16 Dow Agrosciences Llc 在植物中生產二十二碳六烯酸（ｄｈａ）及其他長鏈多元不飽和脂肪酸（ｌｃ－ｐｕｆａ）之技術
US8951776B2 (en) 2011-10-19 2015-02-10 Massachusetts Institute Of Technology Engineered microbes and methods for microbial oil production
KR20140116445A (ko) 2011-12-30 2014-10-02 다우 아그로사이언시즈 엘엘씨 카놀라 가공 동안의 ｄｈａ 유지
US8816111B2 (en) 2012-06-15 2014-08-26 Commonwealth Scientific And Industrial Research Organisation Lipid comprising polyunsaturated fatty acids
AR091774A1 (es) * 2012-07-16 2015-02-25 Dow Agrosciences Llc Proceso para el diseño de las secuencias de adn repetidas, largas, divergentes de codones optimizados
CN110876413A (zh) * 2012-09-11 2020-03-13 美国陶氏益农公司 与dha共混的ω-9芸苔油
AU2014227823A1 (en) 2013-03-15 2015-09-03 Lisa HOLLISTER Genetically modified plants that are insect-resistant and/or rot-resistant
US20140283220A1 (en) * 2013-03-15 2014-09-18 Yi Li Genetically Modified Plants that are Herbivore-Resistant
CN105793427A (zh) 2013-10-04 2016-07-20 美国陶氏益农公司 玉米金属硫蛋白样调节元件及其用途
BR102014025574A2 (pt) 2013-10-15 2015-09-29 Dow Agrosciences Llc elementos regulatórios de zea mays e usos dos mesmos
BR102014025499A2 (pt) 2013-10-15 2015-09-29 Dow Agrosciences Llc elementos regulatórios de zea mays e uso dos mesmos
BR102014029437A2 (pt) 2013-11-26 2015-07-07 Dow Agrosciences Llc Produção de ácidos graxos ômega-3 polinsaturados de cadeia longa em culturas oleaginosas por uma pufa sintase de traustoquitrídio
WO2015196250A1 (en) 2014-06-27 2015-12-30 Commonwealth Scientific And Industrial Research Organisation Lipid comprising docosapentaenoic acid
AU2014366839B2 (en) 2013-12-18 2021-07-01 Commonwealth Scientific And Industrial Research Organisation Lipid comprising long chain polyunsaturated fatty acids
TW201527316A (zh) 2013-12-31 2015-07-16 Dow Agrosciences Llc 新穎玉米泛素啓動子（五）
TW201527312A (zh) 2013-12-31 2015-07-16 Dow Agrosciences Llc 新穎玉米泛素啓動子（一）
TW201527314A (zh) 2013-12-31 2015-07-16 Dow Agrosciences Llc 新穎玉米泛素啓動子（三）
TW201527313A (zh) 2013-12-31 2015-07-16 Dow Agrosciences Llc 新穎玉米泛素啓動子（二）
BR102015000943A2 (pt) 2014-01-17 2016-06-07 Dow Agrosciences Llc expressão aumentada de proteína em planta
EP3099782B1 (en) 2014-01-28 2019-03-20 DSM IP Assets B.V. Factors for the production and accumulation of polyunsaturated fatty acids (pufas) derived from pufa synthases
TW201538518A (zh) 2014-02-28 2015-10-16 Dow Agrosciences Llc 藉由嵌合基因調控元件所賦予之根部特異性表現
CN107532179B (zh) 2014-11-14 2021-10-15 巴斯夫植物科学有限公司 产生pufa的材料和方法及含有pufa的组合物
KR20170136549A (ko) 2015-04-15 2017-12-11 다우 아그로사이언시즈 엘엘씨 트랜스젠 발현을 위한 식물 프로모터
CN107624136A (zh) 2015-04-15 2018-01-23 美国陶氏益农公司 用于转基因表达的植物启动子
TW201718862A (zh) 2015-09-22 2017-06-01 Dow Agrosciences Llc 用於轉殖基因表現之植物啟動子及３’ｕｔｒ
TW201718861A (zh) 2015-09-22 2017-06-01 道禮責任有限公司 用於轉殖基因表現之植物啟動子及３’ｕｔｒ
EP3365451B1 (en) 2015-10-22 2020-06-24 Dow Agrosciences LLC Plant promoter for transgene expression
US20170121726A1 (en) 2015-11-04 2017-05-04 Dow Agrosciences Llc Plant promoter for transgene expression
JP6966040B2 (ja) 2016-05-12 2021-11-10 ディーエスエム アイピー アセッツ ビー.ブイ.Dsm Ip Assets B.V. 微細藻類中でのオメガ−３多価不飽和脂肪酸産生を増加させる方法
EP4338586A3 (en) * 2016-06-16 2024-06-26 Nuseed Nutritional Australia Pty Ltd Elite event canola ns-b50027-4
CN110291199B (zh) 2016-10-03 2023-12-22 美国陶氏益农公司 用于转基因表达的植物启动子
US10519459B2 (en) 2016-10-03 2019-12-31 Dow Agrosciences Llc Plant promoter from Panicum virgatum
CN111278276B (zh) 2017-06-28 2023-05-26 美国陶氏益农公司 用于转基因表达的植物启动子
CN111527212B (zh) 2017-08-31 2024-04-09 科迪华农业科技有限责任公司 使用来自叶绿素结合Ab基因的调控元件表达转基因的组合物和方法
JPWO2020032261A1 (ja) * 2018-08-10 2021-08-10 協和発酵バイオ株式会社 エイコサペンタエン酸を生産する微生物及びエイコサペンタエン酸の製造法
WO2020032258A1 (ja) * 2018-08-10 2020-02-13 協和発酵バイオ株式会社 多価不飽和脂肪酸を生産する微生物及び多価不飽和脂肪酸の製造法
CN109852724A (zh) * 2019-04-03 2019-06-07 深圳出入境检验检疫局食品检验检疫技术中心 转基因油菜品系oxy235检测方法、试剂和试剂盒
EP4430063A1 (en) 2021-11-09 2024-09-18 Benson Hill, Inc. Promoter elements for improved polynucleotide expression in plants
US20250051792A1 (en) 2021-12-15 2025-02-13 Benson Hill, Inc. Spatio-temporal promoters for polynucleotide expression in plants
US20240035100A1 (en) * 2022-06-27 2024-02-01 Monsanto Technology Llc Soybean transgenic event gm_csm63770 and methods for detection and uses thereof
WO2024127362A1 (en) 2022-12-15 2024-06-20 Benson Hill, Inc. Spatio-temporal promoters for polynucleotide expression in plants
WO2025238190A1 (en) 2024-05-15 2025-11-20 Dsm Ip Assets B.V. Spray-dried powders having high pufa content

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL8300698A (nl) 1983-02-24 1984-09-17 Univ Leiden Werkwijze voor het inbouwen van vreemd dna in het genoom van tweezaadlobbige planten; agrobacterium tumefaciens bacterien en werkwijze voor het produceren daarvan; planten en plantecellen met gewijzigde genetische eigenschappen; werkwijze voor het bereiden van chemische en/of farmaceutische produkten.
US5420034A (en) 1986-07-31 1995-05-30 Calgene, Inc. Seed-specific transcriptional regulation
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US5693507A (en) 1988-09-26 1997-12-02 Auburn University Genetic engineering of plant chloroplasts
US5451513A (en) 1990-05-01 1995-09-19 The State University of New Jersey Rutgers Method for stably transforming plastids of multicellular plants
DE69231875T2 (de) 1991-04-09 2001-10-04 Unilever N.V., Rotterdam Pflanzen-promoter involviert in der kontrolle der lipid-biosynthese in samen
US6210700B1 (en) 1997-01-14 2001-04-03 Novartis Nutrition Ag Enhancement of transplant graft survival through nutritional immunomodulation with omega-9 fatty acid dietary supplement therapy
EP1003869A1 (en) 1997-06-04 2000-05-31 Calgene LLC Production of polyunsaturated fatty acids by expression of polyketide-like synthesis genes in plants
US6566583B1 (en) 1997-06-04 2003-05-20 Daniel Facciotti Schizochytrium PKS genes
EP2042603A1 (en) * 1998-11-17 2009-04-01 Monsanto Technology, LLC Phosphonate metabolizing plants
US8003772B2 (en) 1999-01-14 2011-08-23 Martek Biosciences Corporation Chimeric PUFA polyketide synthase systems and uses thereof
US7217856B2 (en) 1999-01-14 2007-05-15 Martek Biosciences Corporation PUFA polyketide synthase systems and uses thereof
US7247461B2 (en) 1999-01-14 2007-07-24 Martek Biosciences Corporation Nucleic acid molecule encoding ORFA of a PUFA polyketide synthase system and uses thereof
US7211418B2 (en) 1999-01-14 2007-05-01 Martek Biosciences Corporation PUFA polyketide synthase systems and uses thereof
US6784342B1 (en) 1999-08-04 2004-08-31 The University Of British Columbia Regulation of embryonic transcription in plants
ATE414779T1 (de) 1999-09-30 2008-12-15 Japan Tobacco Inc Vektoren zum transformieren von pflanzen
US20040049806A1 (en) * 2000-05-24 2004-03-11 Ljerka Kunst Nucleic acid encoding a plant very long chain fatty acid biosynthetic enzyme
CA2409876C (en) 2000-05-24 2012-01-03 The University Of British Columbia Gene regulatory region that promotes early seed-specific transcription
US20040172682A1 (en) 2003-02-12 2004-09-02 Kinney Anthony J. Production of very long chain polyunsaturated fatty acids in oilseed plants
PL1809118T3 (pl) * 2004-11-04 2017-07-31 Monsanto Technology Llc Kompozycje oleju z nasion
WO2006135866A2 (en) 2005-06-10 2006-12-21 Martek Biosciences Corporation Pufa polyketide synthase systems and uses thereof
BRPI0614476B1 (pt) * 2005-08-01 2018-04-03 Her Majesty The Queen In Right Of Canada As Represented By The Minister Of Agriculture And Agri-Food Canada Farinha de canola e ração animal
US7868228B2 (en) 2006-01-31 2011-01-11 Monsanto Technology Llc Phosphopantetheinyl transferases from bacteria
MX340759B (es) * 2006-03-15 2015-03-11 Dsm Ip Assets B V * Aceites de semillas vegetales que contienen ácidos grasos poli-insaturados.
SG10201501004UA (en) * 2006-08-29 2015-04-29 Dsm Ip Assets Bv USE OF DPA(n-6) OILS IN INFANT FORMULA
CA2709067A1 (en) 2007-12-21 2009-07-09 Zhifu Zheng Diacylglycerol acyltransferase 2 genes and proteins encoded thereby from algae
US8455035B2 (en) * 2008-04-25 2013-06-04 Basf Plant Science Gmbh Plant seed oil
US9090902B2 (en) * 2008-08-26 2015-07-28 Basf Plant Science Gmbh Nucleic acids encoding desaturases and modified plant oil
WO2010108114A2 (en) * 2009-03-19 2010-09-23 Martek Biosciences Corporation Polyunsaturated fatty acid synthase nucleic acid molecules and polypeptides, compositions, and methods of making and uses thereof
TW201144442A (en) * 2010-05-17 2011-12-16 Dow Agrosciences Llc Production of DHA and other LC-PUFAs in plants

Also Published As

Publication number Publication date
HK1179652A1 (zh) 2013-10-04
CL2012003210A1 (es) 2013-08-02
CN105296511A (zh) 2016-02-03
ES2656217T3 (es) 2018-02-26
WO2011146524A1 (en) 2011-11-24
EP2571994B1 (en) 2017-12-13
KR102184432B1 (ko) 2020-12-01
US10669554B2 (en) 2020-06-02
NZ604479A (en) 2014-10-31
UA116613C2 (uk) 2018-04-25
MX345243B (es) 2017-01-23
NO2571994T3 (cg-RX-API-DMAC7.html) 2018-05-12
CN103080319A (zh) 2013-05-01
CN103080319B (zh) 2015-11-25
US11168332B2 (en) 2021-11-09
BR112012029255A2 (pt) 2015-09-08
US12006504B2 (en) 2024-06-11
US20190010510A1 (en) 2019-01-10
US20130150599A1 (en) 2013-06-13
PL2571994T3 (pl) 2018-06-29
MY165098A (en) 2018-02-28
IL223045A0 (en) 2013-02-03
JP6059138B2 (ja) 2017-01-11
PH12012502267A1 (en) 2013-02-11
CA2799559C (en) 2022-06-28
AR081201A1 (es) 2012-07-04
US20180073036A1 (en) 2018-03-15
TW201144442A (en) 2011-12-16
US20220170037A1 (en) 2022-06-02
CA3161375A1 (en) 2011-11-24
EA201291223A1 (ru) 2013-05-30
AU2011256209B2 (en) 2016-12-22
PT2571994T (pt) 2018-03-14
AU2011256209A1 (en) 2013-01-10
CA2799559A1 (en) 2011-11-24
SG185572A1 (en) 2012-12-28
EP3354739A1 (en) 2018-08-01
EP2571994A1 (en) 2013-03-27
EP3517617A1 (en) 2019-07-31
EP2571994A4 (en) 2013-10-23
US20200362361A1 (en) 2020-11-19
JP2013529086A (ja) 2013-07-18
KR20130109974A (ko) 2013-10-08
MX2012013401A (es) 2013-09-02

Similar Documents

Publication Publication Date Title
HUE036182T2 (hu) DHA és más LC-PUFA elõállítása növényekben
HUS2100032I1 (hu) Helyettesített 5-fluor-1H-pirazolopiridin-származékok és alkalmazásuk
HUE057004T2 (hu) CD277 elleni antitestek és alkalmazásaik
ZA201508059B (en) Compositions and methods of use of phorbol esters
PL2606120T4 (pl) Ludzkie komórki ułatwiające tolerancję i ich zastosowanie
HUE045656T2 (hu) PHF-tau elleni ellenanyagok és alkalmazásuk
IL232609B (en) Root devices and methods for their production
BR112012031855A2 (pt) composição e artigo
DK2648742T3 (da) Formuleringer indeholdende saponiner og anvendelser deraf
BR112012027165A2 (pt) composição e artigo
PL2655613T3 (pl) Wytwarzanie cząstek podobnych do wirusa w roślinach
IL232262A0 (en) Therapeutic agents and uses thereof
PL2651409T3 (pl) Nowa kompozycja farmaceutyczna zawierająca nlpz i cyklodekstrynę
HUE053623T2 (hu) Vegyületek és azok felhasználása
IL234906A0 (en) Colchicine compositions, methods of production and methods of using them
PL2922557T3 (pl) Suplementy ziołowe i sposoby ich zastosowania
EP2790666A4 (en) MAESA JAPONICA EXTRACTS AND METHOD OF USE THEREOF
HUE036094T2 (hu) Th1 jellemzõket és citolítikus tulajdonságokat expresszáló sejtek
SG10201604468QA (en) Shk-based pharmaceutical compositions and methods of manufacturing and using the same
IL233961A0 (en) The composition of a phytogenic supplement and methods of its use
DK2745839T3 (da) Farmaceutisk sammensætning i form af en oral suspension omfattende en flavonoid-fraktion og xanthangummi
IL217137A0 (en) Medicinal and herbal composition and uses thereof
FR2962457B1 (fr) Greement de chalut et chalut
EP2657236A4 (en) NEW 2-ALKYNYL-N9-PROPARGYLADENINE AND ITS MEDICAL USE
PL390701A1 (pl) Naturalny preparat farmaceutyczno-kosmetyczny